FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma.
The FLIPI24 calculates the probability (%) of event (progression, re-treatment, transformation, or death) within the first two years after starting frontline immunochemotherapy. The model assumes CD20 antibody plus CHOP or bendamustine based chemotherapy with a 50% likelihood of CD20 antibody maintenance. The model data are from the FLIPI24 Consortium, which is comprised of patient data from 10 international cohorts.
MJ Maurer et al,